B. Riley Securities Initiates Coverage On Perspective Therapeutics with Buy Rating, Announces Price Target of $1.2
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Yuan Zhi has initiated coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and set a price target of $1.2.
January 26, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Perspective Therapeutics received a Buy rating from B. Riley Securities with a price target of $1.2, indicating a positive outlook from the analyst.
The initiation of coverage by B. Riley Securities with a Buy rating typically suggests a positive sentiment towards the stock, which can lead to increased investor interest and potentially a rise in the stock price in the short term. The announcement of a price target provides a specific goal that can influence investor expectations and trading behavior.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100